Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde

Journal of Neuroscience Research

Volumn 60, Issue 4, 2000, Pages 552-558

  Lamensdorf, Itschak ^a   Eisenhofer, G ^a   Harvey White, J ^a   Hayakawa, Y ^b   Kirk, K ^b   Kopin, I J ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

3,4 dihydroxyphenylethanol; Complex I; DOPAL; Dopamine; Parkinson's disease

Indexed keywords

3,4 DIHYDROXYPHENYLACETALDEHYDE; 3,4 DIHYDROXYPHENYLACETIC ACID; ALDEHYDE DEHYDROGENASE; ALDEHYDE REDUCTASE; DOPAMINE; DOPAMINE DERIVATIVE; NEUROTOXIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; MITOCHONDRIAL RESPIRATION; NERVE CELL DIFFERENTIATION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRON TRANSPORT; GLUCOSE; HOMOVANILLIC ACID; HUMANS; L-LACTATE DEHYDROGENASE; MITOCHONDRIA; NERVE GROWTH FACTOR; NEURONS; NEUROTOXINS; OXIDATION-REDUCTION; PC12 CELLS; PHENYLETHYL ALCOHOL; RATS; ROTENONE; STRESS; UNCOUPLING AGENTS;

EID: 0034657779     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4547(20000515)60:4<552::AID-JNR14>3.0.CO;2-U     Document Type: Article

References (36)

1. Adamson CR, Emley TE, Herbig LJ, Near JA. 1997. Effects of nerve growth factor on dihydrotetrabenazine binding to PC12 cells. Neurochem Int 30:411-415.
2. Baraldi PG, Simoni D, Manfredini S, Menzaiani E. 1983. Preparation of 3,4-dihydroxy-1-benzenethanol: a reinvestigation. Liebigs Ann Chem 4:684-686.
3. Berridge MV, Tan AS. 1993. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys 303:474-482.
4. Burke WJ, Li SW, Zahm S, Kristal BS. 1999. Neurotoxicity of DOPAL, the MAO metabolite of dopamine: implications for Parkinson disease. Neurobiology 52:A345-A345.
5. Caesura AM, Pletscher A. 1992. The new generation of monoamine oxidase inhibitors. Prog Drug Res 38:271-297.
6. Cohen G. 1976. Alkaloid products in the metabolism of alcohol and biogenic amines. Biochem Pharmacol 25:1123-1128.
7. Colzi A, Musolino A, Iuliano A, Fornai F, Bonuccelli U, Corsini GU. 1996. Identification and determination of 3,4-dihydroxyphenylacetaldehyde, the dopamine metabolite, in in vivo dialysate from rat striatum. J Neurochem 66:1510-1517.
8. + in rat striaral slices. Neurochem Int 33:35-40.
9. Davis VE, Walsh MJ. 1970. Alcohol, amines and alkaloids: possible biochemical basis for alcohol addiction. Science 167:1005-1007.
10. Eisenhofer G, Rundqvist B, Friberg P. 1998. Determinants of cardiac tyrosine hydroxylase activity during exercise-induced sympathetic activation in humans. Am J Physiol 43:R626-R634.
11. Floor E, Leventhal PS, Wang Y, Meng L, Chen W. 1995. Dynamic storage of dopamine in rat brain synaptic vesicles in vitro. J Neurochem 64:689-699.
12. Gonzalez C, Kwok Y, Gibb J, Fidons S. 1979. Effects of hypoxia on tyrosine hydroxylase activity in rat carotid body. J Neurochem 33:713-719.
13. Greene LA, Rein G. 1977. Release, storage and uptake of catecholamines by clonal cell line of nerve growth factor (NGF) responsive pheochromocytoma cells. Brain Res 129:247-263.
14. + / NADH and caused only slight decline of intracellular ATP. Arch Biochem Biophys 337:75-80.
15. Kauppinen RA, Nicholls DG. 1986. Failure to maintain glycolysis in anoxic nerve terminals. J Neurochem 47:1864-1869.
16. Kawamura M, Kopin IJ, Kador PF, Sato S, Tjurmina O, Eisenhofer G. 1997. Effects of aldehyde/aldose reductase inhibition on neuronal metabolism of norepinephrine. J Auton Nerv Syst 66:145-148.
17. Kurz T, Richardt G, Seyfarth M, Schoming A. 1996. Ninexocytotic noradrenaline release induced by pharmacological agents or anoxia in human cardiac tissue. Naunyn Schmiedeberg's Arch Pharmacol 354:7-16.
18. Manna C, Galletti P, Cucciolla V, Moltedo O, Leone A, Zappia V. 1997. The protective effect of the olive oil polyphenol (3,4-dihydroxyphenyl)-ethanol counteracts reactive oxygen metabolite-induced cytotoxicity in Caco-2 cells. J Nutr 127:286-292.
19. Mattammal MB, Haring JH, Chung HD, Raghu G, Strong R 1995. An endogenous dopaminergic neurotoxin: implication for Parkinson disease. Neurodegeneration 4:271-281.
20. Mattammal MB, Chung HD, Strong R. 1993. Confirmation of dopamine metabolite in Parkinsonian brain tissue by gas chromatography-mass spectrometry. J Chromatogr 614:205-212.
21. Mills EM, Gunasekar PG, Pavlakovic G, Isom GE. 1996. Cyanide-induced apoptosis and oxidative stress in differentiated PC12 cells. J Neurochem 67:1039-1046.
22. Mizuno Y, Yoshino H, Ikebe S, Hattori N, Kobayashi T, Shimoda-Matsubayashi S, Matsumine H, Kondo T. 1998. Mitochondrial dysfunction in Parkinson disease. Ann Neurol 44(Suppl 1):S99-S109.
23. Olanow CW, Tatton WG. 1999. Etiology and pathogenesis of Parkinson disease. Annu Rev Neurosci 22:123-144.
24. Pereira C, Santos MS, Oliveria C. 1998. Metabolic inhibition increases glutamate susceptibility on a PC12 cell line. J Neurosci Res 51:360-370.
25. Santos MS, Moreno AJ, Carvalho AP. 1996. Relationships between ATP depletion, membrane potential, and release of neurotransmitters in rat nerve terminals. Stroke 27:941-950.
26. Schapira AH 1993. Mitochondrial complex I deficiency in Parkinson disease. Adv Neurol 60:288-291.
27. Schapira AH. 1998. Human complex I defects in neurodegenerative diseases. Biochem Biophys Acta 1364:261-270.
28. Schoef C, Brass E, Jacobi E, Jorde W, Mocnik W, Neuroth L, Salzer W. 1940. Die synthese des 3-oxo-4-methjoxy-phenylacetaldehyds (Homoisovanillins) und des 3,4-Deoxy-phenylacetaldehydes (Homoprotocatechualdehyds). Liebigs Ann Chem 544:30.
29. Schöming A, Fischer S, Kurz T, Richardi G, Schönung E. 1987. Nonexocytotic release of endogenous noradrenaline in the ischemic and anoxic rat heart: mechanism and metabolic requirements. Circ Res 60:194-205.
30. Seaton TA, Cooper JM, Schapira AH. 1997. Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex 1 inhibitors. Brain Res 777:110-118.
31. Shafeena C, Peers T, Peers C. 1998. Hypoxia evokes catecholamine secretion from rat pheochromocytoma PC-12 cells. Biochem Biophys Res Comm 248:13-17.
32. Shearman MS, Ragan CI, Iversen L. 1994. Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of β-amyloid-mediated cell death. Proc Natl Acad Sci 91:1470-1474.
33. Strong R, Mattammal MB, Andron AC. 1993. Free radicals, the aging brain, and age-related neurodegenerative disorders. In: Yu BP, editor. Free radicals, aging and degenerative disease. Boca Raton: CRC Press, p 223-246.
34. Tabakoff B. 1997. Brain aldehyde dehydrogenases and reductases, In: Biochemistry and function of monoamine enzymes. Weaver N, Youdim MBH, editors. New York: Marcel Dekker. p 629-649.
35. Vaccari A, Saba P. 1995. The tyramine-labeled vesicular transporter for dopamine: a putative target of pesticides and neurotoxins. Eur J Pharmacol 292:309-314.
36. Weiner H, Wang X. 1994. Aldehyde dehydrogenase and acetaldehyde metabolism. Alcohol Alcohol (Suppl 2):141-145.